期刊
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
卷 877, 期 31, 页码 3982-3990出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jchromb.2009.10.008
关键词
Lapatinib; Dasatinib; Liquid-liquid extraction; Liquid chromatography mass spectrometry; Tyrosine kinase inhibitor
资金
- Irish Research Council for Science, Engineering & Technology (IRCSET)
- Irish Higher Education Authority Program of Research in Third Level Institutions (PTRLI Cycle IV)
- Science Foundation Ireland Strategic Research Cluster
- Molecular Therapeutics for Cancer Ireland [08/SRC/B1410]
A highly sensitive and selective liquid chromatography tandem mass spectrometry (LC-MS/MS) method has been developed to quantify cellular levels of the tyrosine kinase inhibitors (TKIs) dasatinib (Sprycel (TM)) and lapatinib (Tykerb (TM), Tyverb (TM)). Cellular samples were extracted with a tert-butyl methyl ether: acetonitrile (3: 1, v/v): 1 M ammonium formate pH 3.5 (8: 1, v/v) mixture. Separation was achieved on a Hyperclone BDS C18 (150 mm x 2.0 mm 3 mu m) column with isocratic elution using a mobile phase of acetonitirile-10 mM ammonium formate. pH 4 (54:46, v/v), at a flow rate of 0.2 mL/min. The TKIs were quantified using a triple quadrupole mass spectrometer which was operated in multi-reaction-monitoring mode employing positive electrospray ionisation. The limit of detection and limit of quantification for lapatinib was determined to be 15 and 31 pg on column, respectively. The limit of detection and quantification for dasatinib was 3 and 15 pg on column, respectively. The method allowed for sensitive and accurate determination of cellular levels of dasatinib and lapatinib. in addition, we examined the potential for this method to be utilised to quantitate other TKIs, using gefitinib, erlotinib, imatinib and sorafenib as examples. In principle, these agents were also quantifiable by this method, however, no drug specific validation studies were undertaken with these TKIs. The data indicates that in the cancer cell-line model, DLKP, significantly more lapatinib accumulates in cells in comparison to dasatinib. Additionally, over-expression of the membrane protein drug transporter, P-glycoprotein (P-gp) a common cancer drug resistance mechanism, greatly reduces the cellular accumulation of dasatinib but not of lapatinib. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据